“duchenne-muscular-dystrophy” Archives

in
Entry Author Date Location
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More 11/03/17 National
No Charm: PTC’s Duchenne Drug Rejected by FDA for Third Time 10/25/17 New York
Phrixus to Launch Clinical Trials for Duchenne Drug in Early 2018 10/16/17 Detroit Ann Arbor
Bio Roundup: Graham-Cassidy, Axovant Fail, SpringWorks Launches & More 09/29/17 National
FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug 09/28/17 New York
Alnylam Data Puts a Nobel Discovery One Step Closer to Approved Drug 09/20/17 Boston
Bio Roundup: RNAi Drama, Immunotherapy Data, Lasker Winners & More 09/08/17 National
Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand 08/25/17 National
Startup Builders, IPO Closers & More: Meet Xconomy’s CEO Award Finalists 08/10/17 Boston
Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist 08/01/17 Boston
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More 06/09/17 National
Woodcock: New Approvals Show FDA Is Adapting to Precision Medicine 05/30/17 National
After Sarepta’s Surprising FDA Nod, CEO Kaye Plans to Resign 04/28/17 Boston
Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 04/27/17 Boston
Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M 04/13/17 New York
Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More 03/31/17 National
Bio Roundup: Trumpcare Wavers, Amgen Courts Payers, Critics Circle PTC 03/24/17 National
Sanders, Cummings to PTC: Price Duchenne Steroid at Import Cost 03/22/17 New York
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
For $140M, PTC Gets Duchenne Drug and a Pricing Controversy from Marathon 03/16/17 New York
First Trial in Sight, Editas Cuts $90M Eye Drug Deal With Allergan 03/14/17 Boston
Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More 03/10/17 National
Nonprofit Seeds Exonics to Fund Push For CRISPR Duchenne Treatment 02/27/17 Boston
Cashing in On Duchenne Approval, Sarepta Sells Voucher to Gilead For $125M 02/21/17 Boston
Bio Roundup: CRISPR Drama, Marathon and PhRMA, the Price of Vision & More 02/17/17 National
His Gene Therapy Near Approval, Spark CEO Wonders: What Price Vision? 02/16/17 New York
CEO Kaye Details Insurance Battle As Sarepta Launches Duchenne Drug 01/10/17 Boston
Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug 01/06/17 National
Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug 12/28/16 Boston
Page 1 of 6 next page »